© 2015 SVMPharma Ltd. All rights reserved.

THE BOTTOM LINE

SHOULD THESE DRUGS HAVE BEEN REMOVED

FROM THE CANCER DRUGS FUND?

A REAL WORLD EVIDENCE ANALYSIS

In April 2015, a number of medications used in metastatic

colorectal cancer are set to be removed from the Cancer

Drugs Fund (CDF) for new patients.

Colorectal cancer is the fourth most

common cancer in the UK with over

15,000 deaths annually. Metastatic

disease is an advanced stage of

cancer involving its spread to other

parts of the body.

The measurement of changes in hospital activity and resource

use can help us understand the real world outcomes of

changes in policy and funding. SVMPharma undertook an

analysis of two key drugs using HES data.

Our results suggest that both drugs are associated with

increased unplanned hospital activity following their use…

To find out more contact us: enquiry@svmpharma.com

Yearly Statistics Colorectal

Cancer

UK

al Cancer

in the UK

CONTACT SVMPHARMA

Vaneet NayarDirector SVMPharma

enquiry@svmpharma.com

Tel: +44 (0) 1252 417030

SVMPharma Ltd

Visit svmpharma.com

Follow @svmpharma

Follow on Google+

Connect via LinkedIn

Get In Touch